Randox acquires Cellix

Create PDF

“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” Peter FitzGerald, managing director of Randox Laboratories, said in a press statement. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows, resulting in better outcomes for patients.”